Loading...
XSTO
XVIVO
Market cap925mUSD
Jul 09, Last price  
283.80SEK
1D
3.05%
1Q
7.50%
Jan 2017
222.50%
IPO
1,284.39%
Name

Xvivo Perfusion AB

Chart & Performance

D1W1MN
XSTO:XVIVO chart
P/E
355.27
P/S
11.01
EPS
0.80
Div Yield, %
Shrs. gr., 5y
3.04%
Rev. gr., 5y
35.19%
Revenues
812m
-1.25%
14,724,00068,922,00084,702,000120,245,000138,177,000148,342,000187,868,000220,838,000179,861,000258,386,000415,292,000597,542,000822,415,000812,165,000
Net income
25m
-85.39%
-769,0008,054,0003,738,0005,131,0001,501,0006,260,00012,685,0004,939,000-43,735,0008,152,00018,427,00091,820,000172,182,00025,163,000
CFO
101m
-9.19%
1,669,00013,464,000-3,741,0008,578,00012,550,00022,190,00023,627,00029,505,000-12,266,000-12,059,00027,856,00046,287,000111,290,000101,066,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Xvivo Perfusion AB (publ), a medical technology enterprise based in Gothenburg, Sweden, specializes in developing cutting-edge solutions for the preservation and perfusion of organs, tissues, and cells, crucial for transplantation. The company's reach spans diverse global markets, including Sweden, the United States, broader North and South America, Europe, the Middle East, Africa, and the Asia Pacific region. Its extensive product lineup features the XVIVO System (XPS), an integrated, ready-to-use cardiac bypass system engineered for secure normothermic ex vivo lung perfusion (EVLP). This is supported by the XPS Disposable Lung Kit, which supplies all necessary sterile consumables. Xvivo Perfusion also provides STEEN Solution, a uniquely formulated buffered extracellular solution for perfusing isolated donor lungs during EVLP procedures. Further offerings include Perfadex Plus, an extracellular, low-potassium, dextran-based electrolyte preservation solution; the XVIVO Silicone Tubing Set for rapid flushing of donor lungs during the procurement phase; and both the XVIVO LS and XVIVO Disposable Lung Set, specialized devices for EVLP. Additionally, the company offers the XVIVO Organ Chamber, a single-use sterile container designed for the temporary holding of isolated lungs before transplantation into a recipient, alongside the XVIVO Lung Cannula Set, another sterile, single-use disposable product. The company was founded in 1998.
IPO date
Oct 08, 2012
Employees
142
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT